Dabigatran has 4 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Trazodone Hydrochloride, Lenacapavir Sodium, Primaquine Phosphate. Patients taking Dabigatran should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 4
- Major
- 1
- Moderate
- 3
Major (1)
- Dabigatran + Trazodone Hydrochloride— Increased risk of bleeding due to serotonin effects on platelet hemostasis with anticoagulant use.
Moderate (3)
- Dabigatran + Lenacapavir Sodium— Lenacapavir increases dabigatran concentration. Refer to DOAC prescribing information for concomitant use with moderate …
- Dabigatran + Primaquine Phosphate— Primaquine may inhibit P-gp, potentially increasing dabigatran concentrations. Monitor for adverse reactions.
- Dabigatran + Sodium Zirconium Cyclosilicate— LOKELMA decreases systemic exposure to dabigatran by elevating gastric pH. Separate administration by at least 2 hours.